MissionIR Articles
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Featured in Cleantech and Climate Change Podcast
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, was featured in a new edition of the Cleantech and Climate Change Podcast issued by Investorideas.com, a global news source and leading investor resource covering clean technology and renewable energy stocks issues. Mullen’s Founder, Chairman and CEO David Michery joined the podcast to discuss recent…
-
MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Investment Research Report
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, was featured in a recent report published by Zacks Small-Cap Research. In the report, Zacks valued BVXV at $12.00/ADS. The publication reads, “On August 25, 2022, BiondVax Pharmaceuticals Ltd. (BVXV)…
-
MissionIRNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Increasing Access to Safe, Legal CBD and THC to Global Consumers
Flora Growth Corp. (NASDAQ: FLGC) is a cannabis cultivator, brand manufacturer and global distributor. “The Canadian company with a productive base of operations in Colombia’s fertile greenbelt is licensed to cultivate cannabis on a 100-hectare (about 247-acre) farming facility and then deliver its product to its GMP-certified processing facility in the nation’s capital, where beauty,…
-
MissionIRNewsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Announces Full Acquisition of Interest in RKings Competitions
Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of gaming platforms, systems and gaming content, has acquired the remaining 20% interest in RKings Competitions; the company now owns a total of 165,444 restricted shares of GMGI’s common stock payable to the two former owners of RKings. Company officials announced the transaction, which makes RKings a…
-
MissionIRNewsBreaks – EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) Benefiting as Utilities Look to Reduce Dependence on Fossil Fuels
EverGen (TSX.V: EVGN) (OTCQX: EVGIF), a leading Canadian renewable energy company and Canada’s renewable natural gas (“RNG”) infrastructure platform, is among companies that are rising to the challenge to provide RNG solutions for utilities increasingly looking to slash pollution and reduce the world’s dependence on fossil fuels. “Climate change awareness has consumers, regulators and companies…
-
MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, is focused on fusing traditional therapeutics with psychedelic research to provide novel treatments for numerous indications, including post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, and other rare neurological disorders. “Silo Pharma is currently developing ketamine treatments for fibromyalgia – a chronic disease that causes pain throughout the…
-
MissionIRNewsBreaks – RYVYL Inc. (NASDAQ: RVYL) Announces Plans to Report Q3 2022 Financial Results
RYVYL (NASDAQ: RVYL), a company that leverages the security of the blockchain and USD-pegged stablecoin technology with near-real-time attestation to conduct payment transactions, is planning to release its third quarter 2022 financial report this month. The company announced that it will release the report on Nov. 14, 2022. On the same day, RYVYL executives will host…
-
MissionIRNewsBreaks – Cepton Inc. (NASDAQ: CPTN) to Participate in 13th Craig-Hallum Alpha Select Conference
Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, today announced that its Chief Executive Officer Dr. Jun Pei and Chief Financial Officer Hull Xu will be participating in the 13th Craig-Hallum Alpha Select Conference. The event is slated to be held in New York City on Nov. 17, 2022. Cepton…
-
MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation Schedule for Upcoming Investor Events
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced its participation in upcoming investor events. The company’s Chief Executive Officer Doug Drysdale will present and host investor meetings at the Jefferies London Healthcare Conference taking place on Nov. 15-17, 2022. Drysdale’s presentation is slated to begin at…
-
MissionIRNewsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Distinctive in Highly Competitive Online Gambling Space
Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, white labels its industry-leading GM-AG System that can be custom-built from 10,000+ game options for its roughly 650 clients serving about 6.8 million end users. “The online gambling space is highly competitive, leading to most of the world’s biggest…
-
MissionIRNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Eyes Steady Growth, Traction in Distinctive Solutions
Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) has grown its operations with numerous improvements to its cloud-based marketplace that simplifies the once-complex process of international over-the-road (“OTR”) cross-border shipping. In addition, Fr8Tech is constantly exploring new ways to create value for its clients, streamline the region’s cross-border shipping process, and carry that over into respective domestic markets.…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Patient in Global Berubicin Trial Evaluating GBM Treatment
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has provided an update on enrollment of its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin…
-
MissionIRNewsBreaks – Knightscope Inc. (NASDAQ: KSCP) Announces New Contracts, Indicative of Company’s Continued Reach
Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), has announced five new contracts. The contracts are with companies across the United States from several different industries. According to the announcement, the companies include an Ohio-based global pharmaceutical manufacturer and distributor of medical and laboratory products, as well as a provider of performance…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures IRB Approval for Human Clinical Nicotine Study
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of independent review board (“IRB”) approval for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon. The 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study will be conducted in current cigarette smokers, wherein each person…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the 5th annual Neuropsychiatric & Psychedelics Drug Development Summit. The summit runs through Nov. 2, 2022, and is being held in Boston. Cybin director of neuropharmacology Amy Reichelt, PhD, will present during the event; her presentation, titled…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical innovator staking out its own position within the competitive field of research, having already progressed to human trials evaluating its novel glioblastoma multiforme (“GBM”) solution, known as Berubicin (or WP744). “Berubicin is a patented doxorubicin (‘Dox’) analog – an anthracycline chemotherapy agent novel in its ability to cross…
-
MissionIRNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Secures LOI for up to $100M to Help Fund next Stage of Growth
Cepton (NASDAQ: CPTN), a Silicon Valley innovator and pioneer within high-performance lidar solutions, has rapidly emerged as a leader amongst its peers – deploying its unique capabilities across a host of different environments, ranging from traffic systems in Cape Town, South Africa, to airport terminal monitoring in the U.S. “Cepton’s long-term automotive Tier 1 partner,…
-
MissionIRNewsBreaks – Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) Ideally Positioned as Cybersecurity Industry Surges
Cerberus Sentinel (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider based in Scottsdale, Arizona, is poised to profit as the cybersecurity industry prepares for rapid growth. A recent Cybersecurity Report published by McKinsey & Company highlighted this forecasted rise, citing a new survey revealing a $2 trillion market opportunity for cybersecurity…
-
MissionIRNewsBreaks – Eloro Resources Ltd.’s (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Drill Program Unearths Significant Proportions of Precious Metals
Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, recently released positive results from its fully financed drill program at its Iska Iska project in Bolivia. “Results from the company’s diamond drilling program – a process that…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Successful Results of Human Clinical Hypertension Study
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study, HYPER-H21-4, may be the first-ever study to indicate a sustained drop in blood pressure (“BP”) in normally active hypertensive patients following multiple weeks of oral cannabidiol (“CBD”) therapy. The study is evaluating Lexaria’s patented DehydraTECH(TM)-CBD capsule formulation. LEXX…
Search Articles
Latest Articles
- Beeline Holdings, Inc. (NASDAQ: BLNE) Clears Debt and Boosts Revenue, On Track to Becoming Cash Flow Positive by Early 2026
- MissionIRNewsBreaks – Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) Highlighted in Cantor Report for Growth Potential and Sector Strength
- MissionIRNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) to Begin Trading as Solmate (NASDAQ: SLMT) on Oct. 3
- Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Builds Domestic Supply Chain Using RapidSX Technology
- Forward Industries Inc. (NASDAQ: FORD) Is ‘One to Watch’